Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Poly (ADP-ribose) polymerase inhibitors in cancer therapy

11 Feb 2025

Abstract excerpt

ABSTRACT: Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have emerged as critical agents for cancer therapy. By inhibiting the catalytic activity of PARP enzymes and trapping them in the DNA, PARPis disrupt DNA repair, ultimately leading to cell death, particularly in cancer cells with homologous recombination repair deficiencies, such as those harboring BRCA mutations. This review delves into the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39932206
DOI: 10.1097/cm9.0000000000003471

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Poly (ADP-ribose) polymerase inhibitors in cancer therapyPMID 39932206Read ↗

Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancersSemantic proximity Read ↗

Targeting DNA repair pathways: mechanisms and potential applications in cancer therapySemantic proximity Read ↗

Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in OncologySemantic proximity Read ↗

Advances and perspectives of PARP inhibitorsSemantic proximity Read ↗

Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer TherapeuticsSemantic proximity Read ↗

The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host InteractionsSemantic proximity Read ↗

The recent advance and prospect of poly(ADP‐ribose) polymerase inhibitors for the treatment of cancerSemantic proximity Read ↗

Therapeutic Targeting of Poly(ADP‐Ribose) Polymerase‐1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future OpportunitiesSemantic proximity Read ↗

PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor ResistanceSemantic proximity Read ↗

Poly(ADP-ribose) polymerase inhibitors as cancer therapySemantic proximity Read ↗

Targeting the DNA Damage Response for Cancer TherapySemantic proximity Read ↗

An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.